• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Aclarion Inc.

    7/9/26 8:00:28 AM ET
    $ACON
    Medical Specialities
    Health Care
    Get the next $ACON alert in real time by email
    S-8 1 aclarion_s8.htm REGISTRATION STATEMENT

    As filed with the U.S. Securities and Exchange Commission on July 9, 2026

     

    Registration No. 333-_____

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    ACLARION, INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   47-3324725
    (State or other jurisdiction of Incorporation or organization   (I.R.S. Employer Identification No.)

     

     

    8181 Arista Place, Suite 100
    Broomfield, CO 80021

    (833) 275-2266

    (Address of principal executive offices) (Zip code)

     

    Aclarion, Inc. 2022 Equity Incentive Plan

    CFO Inducement Stock Option Award dated September 2, 2025

    Commercial Director, Western US Inducement Stock Option Award dated May 6, 2026

    (Full titles of the plans)

     

    Gregory A. Gould

    Chief Financial Officer

    Aclarion, Inc.

    8181 Arista Place, Suite 100
    Broomfield, CO 80021

    (833) 275-2266

    (Name, address, including zip code, and telephone number,

    including area code, of agent for service)

     

    Copies to:

     

    James H. Carroll

    Carroll Legal LLC

    1449 Wynkoop Street

    Suite 507

    Denver, CO 80202

    (303) 888-4859

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

       

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 is filed by Aclarion, Inc. relating to 900,000 additional shares of common stock authorized to be issued pursuant to (i) the Company’s Equity Incentive Plan (as amended through June 4, 2026), and (ii) two outside-of-plan inducement stock option grants made pursuant to Nasdaq Listing Rule 5635(c)(4).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     i 

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for in Part I of Form S-8 to be contained in the Section 10(a) prospectus is not being filed with or included in this registration statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     1 

     

     

    PART II

     

    ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

     

    The following documents filed by Aclarion, Inc. (the “Registrant”) with the SEC are incorporated by reference into this Registration Statement:

     

    ·The Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 18, 2026;
    ·The Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2026 filed with the SEC on May 13, 2026;
    ·The Company's Current Reports on Form 8-K filed on January 9, 2026, January 13, 2026, March 19, 2026, April 22, 2026, and June 4, 2026 to the extent filed and not furnished; and
    ·The description of our securities contained in Exhibit 4.12 to our Annual Report on Form 10-K filed on April 9, 2025, including any amendment or report filed for the purpose of updating such description.

     

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    ITEM 4. DESCRIPTION OF SECURITIES

     

    Not applicable.

     

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

     

    Not applicable.

     

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

     

    Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant’s certificate of incorporation permits indemnification of the Registrant’s directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant’s bylaws provide that the Registrant will indemnify its directors and executive officers and permit the Registrant to indemnify its other officers, employees and other agents, in each case to the maximum extent permitted by the Delaware General Corporation Law.

     

    The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his or her capacity as such.

     

     

     

     2 

     

     

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.

     

    Not applicable.

     

    ITEM 8. EXHIBITS

     

    The following documents are filed as exhibits to this Registration Statement.

     

    Exhibit Number   Description of Document   Incorporated by reference from Form  

    Filing

    Date

      Exhibit Number   Filed Herewith
                         
    3.1   Amended and Restated Certificate of Incorporation of the Company   8-K   04/27/2022   3.1    
    3.2   Certificate of Amendment dated January 3, 2024 to the Amended and Restated Certificate of Incorporation   8-K   01/04/2024   3.1    
    3.3   Certificate of Amendment dated January 29, 2025 to the Amended and Restated Certificate of Incorporation   8-K   01/30/2025   3.1    
    3.4   Certificate of Amendment dated March 26, 2025 to the Amended and Restated Certificate of Incorporation   8-K   03/28/2025   3.1    
    3.5   Bylaws of the Company   8-K   04/27/2022   3.2    
    3.6   Amendment to Bylaws dated June 12, 2024   8-K   06/18/2024   3.1    
    3.7   Certificate of Designation of Series D Junior Participating Preferred Stock of Aclarion, Inc., dated March 19, 2026   8-A   03/19/2026   3.1    
    3.8   Stockholder Rights Agreement, dated as of March 19, 2026, by and between Aclarion, Inc. and VStock Transfer, LLC, as rights agent (which includes the Form of Rights Certificate as Exhibit B thereto)   8-A   03/19/2026   4.1    
    5.1   Opinion of Carroll Legal LLC               X
    23.1   Consent of Haynie and Company, Independent Registered Public Accounting Firm               X
    23.2   Consent of Carroll Legal LLC (included in Exhibit 5.1)                
    24.1   Power of Attorney (included on signature page)                
    99.1   Aclarion, Inc. 2022 Equity Incentive Plan   S-1   01-06-2022   10.4    
    99.2   Amendment dated June 4, 2026 to Aclarion, Inc. 2022 Equity Incentive Plan               X
    99.3   Form of Stock Option Grant Notice and Stock Option Agreement under 2022 Equity Incentive Plan   S-1   01-06-2022   10.20    
    99.4   Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2022 Equity Incentive Plan   S-1   01-06-2022   10.21    
    99.5   Form of Inducement Stock Option Grant Notice and Inducement Stock Option Agreement   10-Q   11/12/2025   10.26    
    107   Filing Fee Table               X

     

     

     

     3 

     

     

    ITEM 9. UNDERTAKINGS

     

    1. The undersigned registrant hereby undertakes:

     

    (a) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (d) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

     

    (i)  Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

     

    (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

     

     

     

     4 

     

     

    (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

     

    (iv)  Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

     

    2. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

     

     

     

     

     

     

     

     

     5 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Mateo, State of California, on July 9, 2026.

     

      ACLARION, INC.
       
      By: /s/ Gregory A. Gould
      Gregory A. Gould
      Chief Financial Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gregory A. Gould and Brent Ness, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Brent Ness   Chief Executive Officer and Director July 9, 2026
    Brent Ness   (Principal Executive Officer)  
           
    /s/ Gregory A. Gould   Chief Financial Officer July 9, 2026
    Gregory A. Gould   (Principal Financial and Accounting Officer)  
           
    /s/ Jeffrey Thramann   Executive Chairman and Director July 9, 2026
    Jeffrey Thramann        
             
    /s/ Stephen Deitsch   Director July 9, 2026
    Stephen Deitsch        
             
    /s/ David Neal   Director July 9, 2026
    David Neal        
             
    /s/ Amanda Williams   Director July 9, 2026
    Amanda Williams        
             
    /s/ Scott Breidbart   Director July 9, 2026
    Scott Breidbart        
             
    /s/ William Wesemann   Director July 9, 2026
    William Wesemann        
             

     

     

     1 

     

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Strategy Officer Bond Ryan was granted 55,000 shares (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    6/12/26 4:30:47 PM ET
    $ACON
    Medical Specialities
    Health Care

    Executive Chairman Thramann Jeffrey John was granted 100,000 shares (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    6/12/26 4:30:37 PM ET
    $ACON
    Medical Specialities
    Health Care

    Chief Financial Officer Gould Gregory A was granted 50,000 shares (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    6/12/26 4:30:42 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    SEC Filings

    View All

    SEC Form S-8 filed by Aclarion Inc.

    S-8 - Aclarion, Inc. (0001635077) (Filer)

    7/9/26 8:00:28 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Aclarion, Inc. (0001635077) (Filer)

    6/4/26 4:49:48 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Aclarion Inc.

    10-Q - Aclarion, Inc. (0001635077) (Filer)

    5/13/26 4:30:39 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ACON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice

    Abstracts presented at American Society of Pain & Neuroscience (ASPN) annual meeting across surgical decision support and basivertebral nerve ablationEarly findings from real-world evidence study demonstrate immense utility and ability of Nociscan to be incorporated into clinical practiceCase study represents first reported use of Nociscan to guide basivertebral nerve ablation in a patient without classic Modic changes on standard MRI, resulting in 95% relief of long-standing chronic low back pain BROOMFIELD, Colo., July 21, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and propri

    7/21/26 7:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Announces Texas Spine Care Center as New CLARITY Site

    Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatmentCLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., July 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algori

    7/7/26 7:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

    BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel. Jeff Thramann, Executive Chairman, will be hosting the presentation and answering questions at the conclusion. Recent Key Highl

    6/10/26 7:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Director Breidbart Scott bought $18,012 worth of shares (5,664 units at $3.18) (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    5/12/26 6:53:21 PM ET
    $ACON
    Medical Specialities
    Health Care

    Director Neal David K bought $7,750 worth of shares (2,500 units at $3.10), increasing direct ownership by 125,000% to 2,502 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    5/12/26 8:30:26 AM ET
    $ACON
    Medical Specialities
    Health Care

    Chief Executive Officer Ness Brent bought $19,999 worth of shares (6,289 units at $3.18), increasing direct ownership by 57,173% to 6,300 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    5/11/26 4:30:21 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Leadership Updates

    Live Leadership Updates

    View All

    Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

    BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 4, 2026. The approved proposals included the election of Jeffrey Thramann, Brent Ness, Stephen Deitsch, Scott Breidbart, David Neal, William Wesemann, and Amanda Williams to the Board of Directors to serve until the 2027 annual meeting, the ratification of

    6/8/26 7:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan

    Commercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical technologiesExpansion of commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization BROOMFIELD, Colo., April 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the appointment of Daniel Keefe as Commercial Director, Western U.S. Dan will lead commercial efforts across

    4/28/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aclarion Inc.

    SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

    11/13/24 3:06:29 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Aclarion Inc.

    SC 13G - Aclarion, Inc. (0001635077) (Subject)

    9/5/24 4:19:39 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Aclarion Inc. (Amendment)

    SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

    3/29/24 5:00:57 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Financials

    Live finance-specific insights

    View All

    Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (NASDAQ:ACON, ACONW)) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to

    3/19/26 9:25:40 AM ET
    $ACON
    Medical Specialities
    Health Care